<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795847</url>
  </required_header>
  <id_info>
    <org_study_id>KurumeU-08058</org_study_id>
    <nct_id>NCT00795847</nct_id>
  </id_info>
  <brief_title>Morning Hypertension and Preminent Therapy Study</brief_title>
  <official_title>The Efficacy and Safety of Losartan/Hydrochlorothiazide Combination Drug (Preminent) in Patients With Morning Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kurume University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kurume University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is difficult to control morning hypertension in practical clinical situation. Angiotensin
      receptor blocker (ARB) and thiazide are suggested to be effective to maintain the
      antihypertensive effects for 24 hours. However, monotherapy sometimes is not enough to
      control blood pressure level in the next morning and there are little evidence of the
      combination therapy for morning hypertension. The investigators hypothesized that a losartan
      50 mg/hydrochlorothiazide 12.5 mg combination drug, Preminent, is effective and safe for
      controling morning hypertension, compared with high-dose of losartan 100 mg, in Japanese.
      Patients with morning hypertension were randomized to preminent treatment group or high-dose
      losartan treatment group. The efficacy and safety were compared after 3-month treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure level in the morning by blood pressure self-measurement</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of potassium, BUN, Creatinine, Uric acid, and Brain natriuretic peptide</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1. Preminent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with blood pressure self-measurement-proven morning hypertension are treated with Preminent 1T qd for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. High-dose losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with blood pressure self-measurement-proven morning hypertension are treated with losartan 100 mg qd for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preminent (losartan/hydrochlorothiazide combination drug)</intervention_name>
    <description>Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.</description>
    <arm_group_label>1. Preminent</arm_group_label>
    <arm_group_label>2. High-dose losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of outpatients with morning hypertension (135/85 mmHg)

          -  Under treatment with any antihypertensive agents

        Exclusion Criteria:

          -  Poorly controlled hypertension (DBP&gt;120 mmHg)

          -  Poorly controlled diabetes (HbA1c&gt;9.0%

          -  Gout or hyperuricemia (UA&gt;8.0 mg/dL)

          -  Serum Cr&gt;2.0 mg/dL

          -  Serum K&gt;5.5 mmol/L

          -  Liver dysfunction (ALT&gt;90 IU/L and/or g-GTP&gt;14o IU/L)

          -  Secondary hypertension

          -  Patients who have contraindication for losartan and/or thiazide diuretics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsutomu Imaizumi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kurume University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hisashi Kai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kurume University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardio-vascular Medicine, Kurume University</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tsutomu Imaizumi/Chair of Cardio-vascular Medicine Kurume University</name_title>
    <organization>Cardio-vascular Medicine Kurume University</organization>
  </responsible_party>
  <keyword>Hypertensive patients with morning hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

